The Role of Tumor-Associated Macrophages in EGFR-TKI Resistance of NSCLC and the Therapeutic Potential of Natural Compounds: A Narrative Review
Article information
Abstract
ABSTRACT
Background:
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved treatment outcomes in non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, the development of acquired resistance remains inevitable. Recent evidence indicates that the tumor microenvironment (TME), particularly tumor-associated macrophages (TAMs), plays a pivotal role in promoting immunosuppression, thereby contributing to EGFR-TKI resistance.
Methods:
A narrative review was conducted using the PubMed and Google Scholar databases for studies published from 2015 to 2025. The search terms included combinations of “lung cancer,” “non-small cell lung cancer,” “EGFR mutations,” “EGFR-TKI resistance,” “tumor microenvironment,” “tumor-associated macrophages,” “macrophage polarization,” “macrophage infiltration,” “natural product,” “herbal extract,” “herbal medicine,” “phytotherapy,” and “natural compound.” Studies examining natural compounds targeting TAMs in NSCLC, with an emphasis on modulation of macrophage polarization and mechanisms of EGFR-TKI resistance, were included.
Results:
TAMs contribute to EGFR-TKI resistance through multiple mechanisms, including activation of bypass pathways, suppression of T cells, and M2 polarization with secretion of immunosuppressive cytokines. We identified 22 natural compounds that effectively reprogram TAMs from an M2 to an M1 phenotype through multiple signaling pathways in vitro and in vivo. These compounds restore tumor-suppressive immunity, illustrating a novel therapeutic strategy to overcome EGFR-TKI resistance.
Conclusion:
Integrating natural compounds that modulate TAM polarization with EGFR-TKI therapy represents a promising strategy to overcome EGFR-TKI resistance in NSCLC. Future research should validate the therapeutic potential of TAM-modulating natural compounds through well-designed clinical trials, standardize herbal formulations, and identify biomarkers or molecular mechanisms in clinical settings.
I. Introduction
Lung cancer is categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the primary contributor to cancer-related mortality globally1. Recent statistics indicate that NSCLC represents about 80% of lung cancer2, and nearly 60% of these patients are diagnosed at advanced stages, leading to unfavorable prognosis3. The epidermal growth factor receptor (EGFR) is a transmembrane protein which activates important downstream signaling pathways, thereby promoting cell growth, differentiation, and proliferation. However, activating EGFR mutations results in its continuous signaling activity, driving the growth and metastasis of NSCLC cells4. Among these mutations, exon 19 deletion and L858R mutation in exon 21 are the most frequent, comprising more than 85% of all EGFR mutations5.
The development of EGFR tyrosine kinase inhibitors (EGFR-TKIs) including gefitinib, afatinib, and the third-generation agent osimertinib has improved clinical outcomes in EGFR-mutated NSCLC6. However, these therapeutic benefits are often transient, as the majority of patients confront acquired resistance through multiple mechanisms. The mechanisms underlying this resistance include secondary EGFR mutations, activation of bypass signaling pathways, and histological or phenotypic changes such as epithelial-mesenchymal transition (EMT) or small cell transformation7.
The tumor microenvironment (TME) represents a multifaceted and dynamic network consisting of cancer-associated fibroblasts (CAFs), endothelial cells, extracellular matrix (ECM) components, and diverse stromal cells including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs)8. Given the heterogeneity of the TME, interactions among stromal cells are crucial in regulating key hallmarks of cancer progression, such as immune suppression, angiogenesis, and inflammation9. Consequently, the role of the TME has acquired increasing interest. Importantly, the TME is considered as a target-abundant landscape for the discovery of novel anticancer agents. While conventional approaches primarily focus on directly targeting cancer cells, stromal cells within the TME have emerged as particularly attractive therapeutic candidates. Unlike tumor cells, stromal cells exhibit genetic stability, making them promising targets that may help reduce drug resistance and tumor recurrence10.
Although multiple components of the TME contribute to cancer progression, TAMs were selected as the primary focus of this review for several reasons. First, TAMs represent one of the predominant immune cell in the TME, constituting about 30-50% of the cellular population in many solid tumors and serving as critical mediators of tumor associated immune infiltration11. Second, TAMs function as central regulators of immune suppression and the TME remodeling through their remarkable phenotypic plasticity, exhibiting diverse functions in cancer progression. M1-like macrophages produce immunostimulatory factors including pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-12, thereby exhibiting potent antitumor effects. Conversely, M2-like macrophages promote tumor progression through angiogenesis, immunosuppression, facilitation of tumor cell metastasis, and support of continuous tumor cell growth. Such functional dichotomy is regulated by complex networks of cytokines, chemokines, signaling cascades, and intercellular communications within the TME12. Third, accumulating evidence indicates that TAMs directly contribute to EGFR-TKI resistance through multiple immunological mechanisms. In NSCLC harboring EGFR mutations, TAMs undergo distinct functional alterations throughout different stages of EGFR-TKI therapy. During the initial phase of treatment, M2 polarization is effectively suppressed. In contrast, with prolonged therapy, resistance to EGFR-TKIs arises, accompanied by an elevation in M2 macrophage populations13. This temporal shift in TAM polarization underscores the dynamic change of the TME during cancer treatment and the necessity of therapeutic strategies that can modulate macrophage function to overcome EGFR-TKI resistance. Finally, among the various TME components investigated as targets of natural compounds, TAMs have received considerable attention because their recruitment, polarization and functional state can be modulated by a wide range of natural compounds. Natural compounds derived from herbal medicines, animals, metabolites, microorganisms, and minerals demonstrate effective anticancer potential against numerous cancers forms, notably lung, breast, colon and prostate cancer14. Their actions involve suppressing the proliferation of tumor cells, antioxidant activity, and anti-inflammation15. Therefore, in this review, the anti-tumor mechanisms of natural compounds targeting TAMs in lung cancer are systematically summarized, focusing specifically on their roles in regulating macrophage polarization and infiltration within the NSCLC tumor microenvironment. The potential of these compounds to overcome EGFR-TKI resistance through macrophage modulation is highlighted, establishing a theoretical basis for further advances of natural compound-based anticancer strategies.
II. Methods
This narrative literature review was conducted using Pubmed and Google scholar to identify studies published between January 2015 and September 2025. The search strategy combined Medical Subject Headings (MeSH) terms and free-text keywords related to NSCLC, EGFR-TKI resistance, TAMs, and natural compounds. Search terms included (“Non-small Cell Lung Cancer” OR “NSCLC”) AND (“EGFR mutation” OR “EGFR-TKI” OR “EGFR-TKI resistance”) AND (“Tumor microenvironment” OR “Tumor-associated macrophages” OR “Macrophage polarization” OR “macrophage infiltration”), together with terms related to natural compounds, including (“natural product” OR “herbal extract” OR “herbal medicine” OR “phytotherapy” OR “natural compound”). Boolean operators (AND and OR), were used to maximize both sensitivity (comprehensive retrieval) and specificity (exclusion of irrelevant articles). Only articles published in English were considered. After removal of duplicates, titles and abstracts were screened for relevance, and potentially eligible full-text articles were reviewed according to predefined inclusion and exclusion criteria.
The inclusion criteria were defined as follows. Articles were considered if they (1) focused on NSCLC, particularly involving patients or models with EGFR mutations or undergoing EGFR-TKI therapy; (2) addressed the roles of TAMs within the NSCLC TME, including macrophage recruitment, polarization or TAM-mediated mechanisms of therapeutic resistance; (3) evaluated the effects of herbal medicines, natural products, or natural compounds on TAMs or EGFR-TKI responsiveness. Original research articles, including in vitro and in vivo, were prioritized, while relevant review articles were used to provide clinical and biological context. Studies focusing exclusively on other cancer types or SCLC, studies unrelated to EGFR mutation, EGFR-TKI resistance, or TAM and TME biology, case reports, editorials, and letters were excluded. Researches reporting only synthetic anticancer drugs, immunotherapies, or targeted therapies without addressing herbal or natural products was also excluded. Publications prior to 2015 were generally excluded, except for landmark references considered necessary to establish the biological or therapeutic context, and non-English language articles were excluded if translations or abstracts were not accessible.
The literature search initially identified 133 articles. After removal of duplicates, 130 records underwent title and abstract screening. Of these, 30 articles were assessed in full text, and 22 studies meeting the eligibility criteria were ultimately included in this review.
III. Results
1. Mechanisms of EGFR-TKI Resistance and the Role of Tumor Microenvironment
1) Tumor cell-intrinsic mechanisms of EGFR-TKI resistance
For patients with NSCLC harboring EGFR mutations, EGFR-TKIs have improved treatment results. Nevertheless, the emergence of drug resistance continues to be a significant barrier to achieving sustained clinical benefit with these agents. Current evidence indicates that resistance mechanisms to EGFR-TKIs can be generally divided into two categories: on-target and off-target mechanisms. On-target resistance arises from additional mutations within the EGFR gene itself, while off-target resistance is driven through alternative pathway activation or phenotypic changes which occur outside of the EGFR gene.
(1) On-target resistance
Among on-target resistance, T790M is the most frequently found in patients receiving first- and second-generation EGFR-TKIs. Consequently, third-generation EGFR-TKIs like osimertinib have become the recommended therapeutic option due to their ability to effectively target T790M-mediated resistance with improved efficacy and safety profiles. However, disease progression eventually occurs during osimertinib treatment, and at that stage, the emergence of the EGFR C797S mutation stands out as the most prevalent on-target resistance to osimertinib16. Less common EGFR mutations also contribute to resistance against EGFR-TKIs. Examples include exon 20 insertion17, mutations arising after resistance to second-generation TKIs such as T854A18, D761Y19, L747S20, and mutations detected following resistance to third-generation TKIs like G796D21.
(2) Bypass pathway activation and downstream signals
Bypass mechanisms of resistance involve the activation of alternative receptor tyrosine kinases (RTK) that can sustain critical downstream signaling pathways of EGFR. Among these, MET amplification and human epidermal growth factor receptor 2 (HER2) upregulation are common bypass mechanisms. EGFR-TKI treatment imposes selective pressure on EGFR-dependent tumor cells, creating a survival advantage for subpopulations that can maintain downstream signaling through alternative RTKs. MET-amplified subclones may pre-exist at low frequencies within heterogeneous tumors or emerge during treatment, and sustained EGFR inhibition can promote their clonal enrichment22. MET gene amplification is particularly notable for its ability to drive resistance by reactivating both PI3K/AKT and MEK/ERK pathways independent of EGFR inhibition, thereby sustaining tumor proliferation and therapeutic resistance23. In addition to such genetic selection, ligand-mediated activation of alternative RTKs may further reinforce resistance. HGF-mediated MET activation can reactivate PI3K/AKT and MAPK/ERK signaling despite EGFR inhibition24. Similarly, HER2 (ErbB2) amplification or overexpression can provide an alternative survival pathway under EGFR inhibition. Such HER2 alterations emerges in approximately 2-10% of EGFR-mutant NSCLC following EGFR-TKI therapy, acting as a bypass resistance mechanism that reactivates PI3K/AKT and MAPK signaling independent of EGFR25. Through sustained activation of these downstream cascades, HER2-driven signaling can therefore functionally substitute for EGFR signaling and promote tumor cell survival despite EGFR inhibition.
(3) Phenotypic transformation
Phenotypic change is another significant off-target mechanism of EGFR-TKI resistance. Approximately 3% to 15% of NSCLC patients experience conversion from NSCLC to SCLC26. Genetic alterations in tumor suppressor genes TP53 and RB1 have been identified as critical drivers initiating this SCLC transformation27. Moreover, squamous cell carcinoma transformation has been documented in about 15% of patients treated with osimertinib, either as first- or second-line therapy, representing an additional mechanism contributing to EGFR-TKIs resistance28. This phenotypic shift represents a challenge in clinical management as it often results in reduced sensitivity to EGFR-TKI therapies.
2) TME-mediated immunological mechanisms of EGFR-TKI resistance
EGFR mutations are frequently associated with a weakly immunogenic TME, characterized by limited antigenicity and insufficient immune activation, which contributes to poor antitumor immune response29. However, EGFR-TKI treatment improves the anti-tumor immune response through several mechanisms. First, EGFR-TKIs upregulate the expression of major histocompatibility complex (MHC) class I through MEK-ERK pathway inhibition, thereby augmenting T cell-mediated cytotoxicity30. Second, EGFR-TKIs remodel the TME by reducing immunosuppressive Treg infiltration, increasing cytotoxic CD8⁺ T cell infiltration and dendritic cell maturation while temporarily inhibiting macrophage polarization toward the immunosuppressive M2 phenotype.
But these beneficial immune changes are not sustained. With prolonged EGFR-TKI exposure, the tumor reactivates IL-10/Signal transducer and activator of transcription 3 (STAT3) signaling, which reactivates Treg activity, impairs CD8+ T cell activation, suppresses dendritic cell function, and promotes M2 macrophage polarization31. Additionally, resistant tumors suppress human leukocyte antigen (HLA) expression and peptide processing, thereby impairing antigen presentation. HLA, the MHC molecules in humans, presents peptide fragments that allow identification and elimination of tumor cells by CD8⁺ T cells32. These dynamic shifts suggest that while EGFR-TKIs transiently reprogram the TME to favor anti-tumor immunity, resistance mechanisms and TME heterogeneity ultimately constrain the durable efficacy of immunotherapy in this molecular subset (Table 1).
3) Mechanism of TAMs contributing to EGFR-TKI resistance
TAMs are crucial contributors to disease progression and EGFR-TKI resistance. The mechanisms by which TAMs mediate resistance are multifaceted and involve complex interactions within the TME that ultimately undermine therapeutic efficacy and promote tumor survival (Fig. 1).
The mechanisms of TAMs contributing to EGFR-TKI resistance.
M2-polarized TAMs secrete EREG, which binds with ErbB2 receptor on NSCLC cells, activates AKT and induces drug resistance. TAMs also secrete exosomes, which activate downstream pathways in tumor cells such as AKT, ERK 1/2, and STAT3. In addition, EGFR-TKI treatment elevate CCL2 level, which recruit M2 macrophages. TAMs mediate EGFR-TKI resistance through direct suppression of cytotoxic CD8+ T cell function and express high level of iNOS and PD-L1, both of which inhibit T cell proliferation and increase tumor aggressiveness in NSCLC. AKT : Protein kinase B, CCL2 : C-C motif ligand 2, EGFR : Epidermal growth factor receptor, EREG : Epiregulin, ERK 1/2 : Extracellular signal-regulated kinase 1/2, iNOS : Inducible nitric oxide synthase, NSCLC : Non-small cell lung cancer, PD-L1 : Programmed death-ligand 1, STAT3 : Signal transducer and activator of transcription 3, TAM : Tumor-associated macrophages, TKI : Tyrosine kinase inhibitor. Created with BioRender.com (https://biorender.com/, accessed on 13 October 2025).
(1) Bypass pathway activation
TAMs facilitate EGFR-TKI resistance largely by activating alternative signaling cascades that bypass EGFR inhibition. Treatment with EGFR-TKIs has been reported to elevate serum levels of chemokine (C-C motif) ligand 2 (CCL2), a crucial intermediary in the development of EGFR-TKI resistance31. Xiao et al.33 demonstrated that tumor cells secrete CCL2 to recruit M2-polarized macrophages, which subsequently promote gefitinib resistance through activation of the AKT/mTOR pathway, a pivotal modulator of cell proliferation which sustains tumor cell survival despite EGFR inhibition. Furthermore, activation of AKT upregulates immune checkpoint molecules such as programmed death-ligand 1 (PD-L1), which plays a key role in tumor immune evasion by binding to PD-1 receptors on T cells and inhibiting their function. In addition, AKT activation promotes the secretion of immunosuppressive cytokines, further contributing to the suppression of anti-tumor immune responses34.
Moreover, TAM-derived exosomes, known to influence tumor progression and metastasis, have been shown to mediate resistance to EGFR-TKIs by triggering AKT, ERK1/2, and STAT3 signaling pathways35. The STAT3 pathway serves as a particularly important crossroads for multiple tumor-related signaling cascades. EGFR T790M-cis-L792F mutations enhance STAT3 phosphorylation at Tyr705 site, leading to increased transcription of interleukin-4 (IL-4) and promoting M2 polarization36. This establishes a positive feedback loop in which resistant tumor cells amplify M2 TAM recruitment, thereby reinforcing the development of resistance. In addition to these mechanisms, TAM-derived growth factors can directly activate alternative RTKs and thereby reinforce bypass signaling during EGFR inhibition. HGF, a ligand for MET, can be secreted by M2 macrophages and activate MET-dependent survival signaling, providing a paracrine mechanism by which tumor cells can maintain downstream signaling despite EGFR blockade37. Similarly, previous studies have demonstrated the critical involvement of epiregulin (EREG), an endogenous ligand of EGFR, in promoting the progression of NSCLC38. Importantly, EGFR-TKI resistant tumor cells reprogram macrophages to produce EREG, and these EREG-secreting TAMs induce resistance to first-generation EGFR-TKIs through activation of AKT phosphorylation via an ErbB2 (HER2)-dependent mechanism, which bypasses EGFR inhibition39.
(2) T-cell suppression
TAMs mediate EGFR-TKI resistance through direct suppression of cytotoxic T cell function. Lin et al.40 demonstrated that TAM accumulation impairs CD8+ T cell activation in NSCLC patients receiving osimertinib treatment, creating an immunosuppressive tumor microenvironment that attenuates the anti-tumor efficacy of EGFR-TKIs. Importantly, reprogramming macrophages using stimulator of interferon genes (STING) agonists such as MSA-2 successfully restored CD8+ T cell activation and sensitivity to osimertinib. Morandi et al.41 further revealed that TAMs inhibit both T lymphocytes and NK cells via expression of nonclassical MHC class I molecules (HLA‐E and HLA‐G) that interact with CD94 and leukocyte immunoglobulin-like receptor subfamily B member 1 (LIR1) to block immune recognition. In addition, TAMs express high levels of inducible nitric oxide synthase (iNOS) and PD-L1, both of which inhibit T cell proliferation and promote tumor growth, invasion, and metastasis in NSCLC42,43.
(3) M2 polarization of TAMs
Macrophage polarization, defined as the process by which macrophage function is regulated by local microenvironmental signals, represents a dynamic and reversible activation state rather than a fixed phenotype. This plasticity is particularly pronounced within the TME, where TAMs exhibit remarkable heterogeneity and can be reprogrammed by changing cytokine and chemokine signals44.
TAMs exist along a polarization continuum anchored by two primary phenotypes. M1 macrophages, which are classically activated, and M2 macrophages, alternatively activated, form the two phenotypes. M1 polarization typically occurs in inflammatory environments under the influence of granulocyte-macrophage colony-stimulating factor (GM-CSF), Th1 cytokines such as interferon-γ (IFN-γ), and Toll-like receptor agonists including lipopolysaccharide (LPS)45. These macrophages secrete pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, IL-12, IL-23, and TNF-α. M1 macrophages also produce inducible nitric oxide synthase (iNOS) and reactive oxygen species (ROS), facilitating the recruitment of CD8+ T cells and NK cells for tumor cell elimination46.
In contrast, M2 macrophages, which are induced by tumor-derived cytokines, including IL-4, IL-10, IL-13, and transforming growth factor-β (TGF-β), facilitate angiogenesis, suppress immune responses, promote tumor cell metastasis, and support tumor progression47. M2 polarization involves multiple signaling pathways, with IL-4 and IL-13 promoting M2 differentiation through STAT6 and PI3K signaling, while IL-10 from regulatory T cells activates the M2 phenotype via STAT348. Therefore, strategies to deplete M2 macrophages or reverse them toward an M1 phenotype hold promise for overcoming EGFR‐TKI resistance in NSCLC.
Collectively, current evidence does not support a strictly unidirectional model in which TAMs uniformly precede or follow the development of EGFR-TKI resistance. Instead, their role appears to be context- and treatment stage-dependent. During EGFR-TKI treatment, tumor-derived signals such as CCL2 can promote macrophage recruitment and polarization, and these reprogrammed macrophages subsequently enhance tumor cell survival through activation of pathways such as AKT/mTOR. Conversely, emerging resistant tumor cells can further reshape the macrophage compartment; for example, activation of the STAT3/IL-4 axis in resistant tumor cells promotes M2 polarization, while EGFR-TKI resistant tumor cells can induce macrophage derived EREG, which reinforces resistance through ErbB2-dependent AKT signaling. Thus, rather than acting solely as either initiators or consequences of resistance, TAMs and tumor cells appear to engage in a dynamic bidirectional interaction. This crosstalk may establish a positive feedback loop in which tumor cell adaptation promotes TAM recruitment and reprogramming, while TAM-derived signals further support the survival and progression of resistant tumor cells.
2. Targeting TAMs to Overcome EGFR-TKI Resistance
1) TAM as a novel therapeutic target for lung cancer
TAMs are the predominant immune cell population within the TME of lung cancer and mediates its progression. Consequently, TAMs have arisen as favorable targets for lung cancer immunotherapy. Current approaches focus on two main strategies: reducing TAM infiltration by blocking their recruitment or survival, and reprogramming M2 macrophages toward antitumor M1 macrophages11.
First, blocking cytokines and chemokines that drive macrophage accumulation such as CSF1 and CCL2 can decrease TAM infiltration. Inhibitors of CSF1R or neutralizing antibodies against CCL2 disrupt monocyte recruitment, effectively reducing TAM burden49,50. Second, inhibiting M2-associated cytokines like CCL22 can diminish the immunosuppressive functions of M2-TAMs51. Third, repolarizing TAMs from M2 to M1 phenotype restores their cytotoxic capacity; for example, anti-IL-10 receptor antibodies and CD40 agonists have been shown to convert M2 macrophages into M1 macrophages and differentiate monocytes to M1 macrophages52,53. Finally, because TAMs exhibit defective NF-κB signaling-a pathway essential for Th1 cytokine expression-therapies aimed at restoring NF-κB function may further enhance antitumor immunity54.
Despite these advances, targeting TAMs faces significant challenges due to their high plasticity and heterogeneity. Pathway inhibitors often affect other immune cells, and indiscriminate depletion of macrophages can increase infection risk. Therefore, macrophage reprogramming has emerged as the preferred strategy because it balances therapeutic efficacy with safety: by preserving peripheral macrophage function while selectively converting tumor-resident M2 macrophages into M1 phenotype, it overcomes the limitations of indiscriminate macrophage depletion strategies and enhances the therapeutic efficacy of current lung cancer treatments55.
2) Unique advantages of natural compounds in TAMs modulation
Natural compounds including polyphenols, polysaccharides, flavonoids, quinones, and saponins demonstrate remarkable therapeutic potential through their ability to regulate multiple tumor-related targets via diverse mechanisms56. These compounds offer significant clinical advantages: cost-effectiveness, accessibility, and ease of administration, making them highly suitable for clinical application. Their primary antitumor activity stems from modulating TAM polarization and infiltration, thereby reshaping the tumor microenvironment to support immune surveillance, enhance lung cancer cell elimination, and prevent tumor immune evasion11 (Fig. 2).
The role of natural compounds in TAMs modulation.
Natural compounds suppress M2 macrophage polarization or promote repolarization toward M1 phenotype, thereby enhancing cytotoxic immune responses and inhibiting tumor progression. Created with BioRender.com (https://biorender.com/, accessed on 13 October 2025).
Each class of natural compounds exhibits distinct yet complementary mechanisms of action. Polyphenols primarily suppress lung cancer cell formation by inhibiting macrophage recruitment and promoting favorable polarization states57. Polysaccharides demonstrate dual functionality through cytotoxic effects against tumor cells and simultaneous enhancement of M1 macrophage polarization, effectively countering the tumor-promoting activities of M2 macrophages58. Alkaloids target both tumor growth and metastasis by comprehensively regulating TAM polarization and infiltration patterns within the tumor microenvironment59. Flavonoids address the inflammatory component of cancer progression by suppressing cytokine translational activity in macrophages, while simultaneously promoting M1 polarization to create an antitumor microenvironment60. Similarly, quinones exert their anticancer effects through a dual approach: reducing macrophage-mediated chronic inflammation and facilitating the phenotypic conversion from immunosuppressive M2 to tumoricidal M1 macrophages61. Finally, saponins enhance antitumor immunity by strengthening M1 macrophage polarization while concurrently reducing inflammatory process that favor tumor progression62. This multi-targeted approach positions natural compounds as promising adjuvants to conventional lung cancer therapies, offering the potential to overcome current limitations in TAM-directed immunotherapy through their inherent safety profile and broad mechanistic diversity.
3. Regulation of TAM by natural compounds: Research progress
Recent preclinical studies have identified a diverse array of natural compounds capable of modulating macrophage polarization and associated intracellular signaling pathways. Such bioactive molecules not only reprogram macrophage function but also reshape the immunological landscape of tumors, offering a foundation for novel therapeutic approaches. The natural compounds summarized in Table 2 share the ability to reprogram macrophage function by targeting key intracellular signaling cascades and shift the TAM balance toward an M1 phenotype, thereby restoring antitumor immunity and inhibiting NSCLC progression. Importantly, these findings should be distinguished from direct evidence of EGFR-TKI resistance reversal, as most studies did not specifically evaluate the restoration of EGFR-TKI sensitivity in EGFR-mutant NSCLC models. Accordingly, the potential of these compounds to overcome EGFR-TKI resistance is largely inferred from their effects on TAM-related mechanisms implicated in EGFR-TKI resistance, rather than directly demonstrated.
Among the most extensively studied pathways are NF-κB/STAT3, STING/TBK1/IRF3, AMPK, and TLR4. For example, dihydroisotanshinone I, an active ingredient of Salvia miltiorrhiza, inhibits STAT3 phosphorylation, thereby reducing macrophage-mediated tumor cell migration and recruitment in A549 cocultures. Moreover, it downregulates the expression of CCL2, further imparing the ability of lung cancer cells to attract macrophages63. Pterostilbene, a polyphenol isolated from Pterocarpus santalinus downregulates the MUC1/NF-κB axis, suppressing M2-type TAM polarization in A549 and H441 cells64. Vanillic acid, present in Angelica sinensis and Panax ginseng, activates the STING pathway to promote M1 differentiation and CD8+ T cell activity in H1299 macrophages65. Lapachol from Handroanthus chrysanthus and related species reverses M2 programming via NF-κB activation in LLC models66. Arsenic trioxide suppresses Notch-dependent CCL2/IL-1β paracrine signaling to block M2 polarization in RAW264.7 and LLC xenograft models67. Likewise, polysaccharides from Moringa oleifera leaves engage TLR4 on RAW264.7 cells and LLC tumors, thus driving M1 polarization with enhanced production of IL-6 and TNF-α68. Puerarin (Radix Puerariae) inhibits MEK/ERK1/2 to prevent M2 differentiation in A549 xenografts69. Dioscin from Dioscorea species impedes JNK/STAT3 signaling to limit M2 polarization in RAW264.7 and LLC-bearing mice70. Matrine (Sophora flavescens) targets the mTOR/PI3K/Akt cascade, effectively suppressing M2-associated markers across multiple macrophage and lung cancer models71. In a similar manner, Sophoridine (Sophora alopecuroides) enhances M1 polarization via activation of the MAPK pathway in both H460 and LLC models72. Likewise, Atractylenolide II, isolated from Atractylodes macrocephala, inhibits STAT6 signaling, thereby attenuating M2-driven metastatic processes in A549 and LLC tumors73. Notably, Astragaloside IV, a natural saponin from Astragali radix, counteracts IL-4/IL-13-induced M2 polarization through AMPK signaling pathway in A549, H1299, and LLC-bearing mice74, whereas Resveratrol derived from Polygonum Cuspidatum suppresses STAT3 activation, and the downregulation of IL-10, Arg1, and CD206 expression, thus diminishing M2 macrophage activity in similar models75. Furthermore, Yeast-derived β-glucan engages dectin-1 receptor to reprograms M2 macrophages toward an M1 phenotype in LLC-bearing mice76, polyphyllin VII from Rhizoma Paridis exerts dual regulatory effects by activating the STING/TBK1/IRF3 axis and inhibiting STAT3 phosphorylation, thereby amplifying M1 polarization77, and sanguinarine, an alkaloid obtained from Sanguinaria canadensis blocks NF-κB signaling in A549 cells to shift THP-1 macrophages toward an M1 phenotype78. Although mechanistic details vary, these compounds inhibit M2 polarization, block macrophage recruitment, and suppress M2-associated cytokines, highlighting the therapeutic potential of targeting TAM-supportive signaling pathways to impede tumor progression.
In parallel, a distinct subset of natural products demonstrates clear TAM repolarization from M2 to M1 phenotype, although their precise molecular mechanisms remain to be fully elucidated. Ginsenoside Rh2, an active component from Panax ginseng, effectively repolarizes M2 macrophages toward the M1 subset. Flow cytometry analysis revealed a marked reduction in the M2 marker CD206 alongside an upregulation of the M1 markers CD16 and CD32 following ginsenoside Rh2 treatment. Additionally, ginsenoside Rh2 significantly decreased both secretion and expression of VEGF-C, MMP-2, and MMP-9, thereby inhibiting lung cancer cell proliferation and migration79. Baicalin from Scutellaria Radix similarly induces M1 polarization and amplifies inflammatory responses. Baicalin increased secretion of M1-related cytokines, including iNOS and TNF-α, and decreased secretion of M2-related cytokines such as VEGF-A and TGF-β in A549 cells80. β-Elemene from Curcuma wenyujin and 13-methyl-palmatrubine from Corydalis yanhusuo both drive M1 polarization in vitro and suppress tumor burden by over 50% in xenograft models81,82. Astragalus polysaccharide (PG2) enhances M1 cytokines while attenuating IL-4/IL-13-induced M2 markers in NSCLC H441 and H1299 cells83. In addition, Wu et al.84 demonstrated that paeoniflorin from Paeonia lactiflora Pallas suppressed lung cancer metastasis through reduction of IL-4 and suppression of M2 macrophage activation.
Collectively, the natural compounds summarized in Table 2 illustrate a novel therapeutic strategy: to induce macrophage repolarization from M2 to M1 phenotype through multi-target modulation, and thereby restore antitumor immune function within the TME. To accelerate clinical application, future work should explore combination regimens pairing natural compounds with EGFR-TKIs in EGFR-mutant NSCLC models, evaluate safety and pharmacokinetics, and develop biomarkers to monitor TAM repolarization. Such integrated strategies promise to convert an immunosuppressive TME into an immunostimulatory state, potentially overcoming resistance and improving patient outcomes.
IV. Conclusion
Over the past decade, EGFR-TKIs have transformed the therapeutic landscape of advanced NSCLC, offering notable advantages over conventional chemotherapy, including improved efficacy, better tolerability, reduced adverse events, elongated survival, and enhanced quality of life for patients. Despite these remarkable clinical efficacies, the issue of acquired drug resistance by secondary mutations, activation of bypass signaling pathways, and the complex molecular crosstalk within the TME collectively limit the long-term benefits of targeted therapy. The majority of patients treated with first- or second-generation EGFR-TKIs inevitably develop acquired resistance within 9 to 13 months85. Even when osimertinib, a 3rd-generation EGFR-TKI, is administered as first-line therapy, resistance also emerges after a median of 18.9 months6.
In this context, the modulation of TAM has emerged as a particularly promising approach to overcome EGFR-TKI resistance. TAM, a key stromal component of TME, exist primarily in two polarized states: tumor-suppressive M1 phenotype and tumor-promoting M2 phenotype. The predominance of M2 macrophages correlates with immune evasion, angiogenesis, and metastasis, thereby facilitating tumor progression and resistance to EGFR-TKI therapy.
While TAM-directed therapy represents a rational therapeutic strategy, clinical translation of single- pathway TAM-targeting agents has encountered significant limitations. Conventional synthetic approaches including CSF-1R inhibitors (e.g., emactuzumab, LY3022855), PI3K-γ inhibitors (e.g., IPI-549/egisib), and CD47/SIRPα blockade have demonstrated modest efficacy as monotherapy or in combination with checkpoint inhibitors in clinical trials. Phase 1b/2 studies of emactuzumab combined with atezolizumab achieved median progression-free survival of only 2.6 months in NSCLC patients86, while LY3022855 combined with durvalumab or tremelimumab yielded a complete response rate of just 1.4% and partial response rate of 2.8%87. Similarly, PI3K-γ inhibition combined with nivolumab in the Phase 1/1b MARIO-1 trial (NSCLC Part E expansion cohort), the NSCLC-specific overall response rate was notably lower at 5% (1 of 20 patients), with median progression-free survival of only 2.1 months88. Selective SIRPα blockers showed improved efficacy compared to anti-CD47 monoclonal antibodies, with an objective response rate of 16.2% as monotherapy and 28.3% in combination approaches in solid tumors. However, this meta-analysis of 24 eligible clinical trials (771 evaluable patients) reveals that combination SIRPα blockade with checkpoint inhibitors demonstrates insufficient response rates to overcome complex resistance mechanisms of EGFR-TKI89. These clinical experiences underscore a critical insight: single-pathway modulation of TAM biology, despite preclinical promise, remains insufficient to durably overcome the complex immunosuppressive tumor microenvironment of EGFR-TKI-resistant NSCLC.
Given these limitations, natural compounds offer a unique complementary strategy due to their multi-target regulatory mechanism. They influence multiple molecular targets simultaneously and contribute to the modulation of the internal microenvironment in cancer, restoring physiological balance and potentially reversing drug resistance. Particularly, this systematic regulatory capacity is relevant in modulating the TAMs. Accumulating evidence reviewed here indicates that several natural compounds can suppress M2 polarization while promoting M1 activation, thereby reprogramming the immunosuppressive microenvironment and restoring antitumor immunity. These compounds also regulate cytokine signaling and epigenetic modifications, reinforcing immune surveillance and cytotoxic responses. Despite the TAM-modulatory effects demonstrated by the natural compounds included in this review, direct evidence that these compounds restore EGFR-TKI sensitivity remains limited. Most available studies have investigated macrophage polarization, infiltration, or general antitumor effects rather than EGFR-TKI resistance itself.
Nevertheless, a growing number of clinical studies have shown that herbal medicine or TCM, many of which possess TAM-modulating properties, can enhance the therapeutic outcomes when combined with EGFR-TKIs in patients with EGFR-mutated NSCLC. A comprehensive analysis utilizing Taiwan’s National Health Insurance Database examined treatment outcomes in 1,988 patients diagnosed with EGFR-mutated advanced lung adenocarcinoma. The investigation revealed substantial survival benefits among patients receiving combined TCM and EGFR-TKI therapy compared to monotherapy approaches. Notably, patients maintaining TCM adjuvant treatment for at least 180 days demonstrated a remarkable 68% reduction in mortality risk (adjusted HR=0.32, [95% CI 0.21-0.50], p<0.0001), alongside a 59% decrease in disease progression risk (adjusted HR=0.41, [95% CI 0.29-0.58], p<0.0001)90. A multicenter, randomized, open-label trial evaluated the Korean herbal formulation HAD-B1 (HangAmDan-B1) in combination with afatinib among 90 patients with EGFR-mutated NSCLC. While statistical significance was not achieved for primary endpoints including dose maintenance rates and disease control rates, the combination group demonstrated significantly improved physical functioning scores (p=0.0475) and reduced adverse event incidence compared to controls (p=0.01), indicating a superior tolerability profile91. Moreover, multiple systematic reviews and meta-analyses have consistently demonstrated the therapeutic advantages of integrative approaches. Zhang et al.92 conducted an extensive analysis encompassing 64 randomized controlled trials involving 4,384 patients, revealing significant improvements in progression-free survival, median survival duration, and both one-year and two-year survival rates with combination therapy versus EGFR-TKI monotherapy. Similarly, Lu et al.93 analyzed 9 RCTs (1,137 participants) and confirmed that combined treatment improved median PFS (HR=0.59, [95% CI 0.52-0.68], p<0.00001) and objective response rate (RR=1.23, [95% CI 1.13-1.34], p<0.00001) compared with conventional EGFR-TKI monotherapy. While these trials do not directly evaluate TAM-focused mechanisms, their clinical benefits suggest that immunomodulation, including TAM reprogramming, may contribute to overcoming EGFR-TKI resistance.
However, these clinical findings do not establish whether the observed benefits are specifically attributable to TAM modulation or reversal of TAM-mediated EGFR-TKI resistance. Therefore, the current clinical evidence should be interpreted as supportive of the potential value of combination strategies rather than as direct validation of the TAM-targeting mechanisms described in preclinical studies. Beyond this mechanistic limitation, the clinical application of many natural compounds remains limited by their structural complexity, poor solubility, low bioavailability, and a lack of standardized treatment protocols. To address these challenges, efforts are underway to enhance the clinical utility of natural products through chemical modification and formulation with advanced drug delivery systems94, prolong systemic circulation, and reduce off-target toxicities95. Such efforts will enable the identification of precise molecular targets and inform rational design of more effective therapeutic agents. Concurrently, well-designed clinical trials with standardized protocols and rigorous efficacy endpoints are indispensable to validate safety and therapeutic benefits, facilitating the translation of preclinical discoveries into clinical practice.
Collectively, these insights highlight that integrating natural compounds or TCM with EGFR-TKIs represents a promising and innovative strategy to overcome EGFR-TKI resistance in NSCLC. By simultaneously targeting multiple molecular pathways and modulating the tumor immune microenvironment, particularly through TAM regulation, this integrative approach may pave the way toward more durable, personalized, and less toxic therapeutic paradigms for lung cancer management.